Palleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting

WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present new findings from a study leveraging its HYDRA platform that suggests a link between stromal hypersialylation and immunosuppression activity within the colorectal tumor microenvironment at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place in San Diego from November 1-5, 2023.

The poster will include the specifics of the study which was conducted in collaboration with the University of Galway. The study revealed that both tumor cells and tumor-associated stromal cells are hypersialylated in the colorectal tumor environment. Additionally, removing sialic acids from stromal cells using an engineered human sialidase (EAGLE) reversed stromal cell-mediated immunosuppression in the co-culture of T cells and cancer-associated fibroblasts derived from colon cancer patients.

Details of the poster presentation are as follows:

Presentation Type: Poster Presentation (Abstract: #1438)

Title: Stromal hypersialylation within colorectal tumors contributes to immunosuppression of T cell adaptive immunity in the tumor microenvironment

Session: Poster Hall Session

Timing: November 4, 2023, 9:00 a.m. – 8:30 p.m. PDT

Location: Exhibit Halls A and B1 – San Diego Convention Center

The poster will appear on Palleon Pharmaceuticals’ website following the presentation.

About Palleon Pharmaceuticals

Palleon is a biotechnology company pioneering glycobiology drug development to transform the treatment of cancer and inflammatory diseases. The company was founded based on discoveries from 2022 Nobel Laureate Carolyn Bertozzi of the central role cell surface glycans play in immune regulation, and how certain glycan patterns can cause immune dysfunction in disease. Palleon’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery as well as patient selection to de-risk clinical development. The company’s lead program in oncology, E-602, is a first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans in patients who have hypersialylated tumors and immune cells. It is being evaluated in a Phase 1/2 clinical trial. Palleon has a rich pipeline of additional drug candidates in cancer and autoimmunity, including several advancing toward IND-enabling studies.

Contacts

Palleon Media Contact
Kit Rodophele

Ten Bridge Communications

[email protected]
(617) 999-9260